Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTARA THERAPEUTICS, INC.

(TARA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protara Therapeutics Announces Results from A Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition

09/13/2021 | 07:00am EDT

Protara Therapeutics, Inc. announced the completion of a retrospective prevalence study designed to enhance understanding of the incidence of intestinal failure associated liver disease (IFALD) in patients dependent on parenteral nutrition (PN). The study found that approximately 30% of patients who are dependent on PN have cholestasis, a hallmark pathology of IFALD, despite the use of current medical management in these patients. The Company is currently developing intravenous (IV) Choline Chloride, an investigational phospholipid substrate replacement therapy, for the treatment of patients receiving PN who have IFALD. In order to further characterize the prevalence and needs of IFALD patients dependent on PN, the Company recently initiated a prospective, multi-center, cross-sectional observational study that will assess the prevalence of choline deficiency, as well as cholestasis and steatosis, in approximately 300 patients dependent on PN. The Company expects to use the results from the completed retrospective study and ongoing prospective study to inform next steps for its IV Choline Chloride development program. As previously announced, the Company held a positive end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and received feedback on the design of studies necessary to complete the registration package for IV Choline Chloride for the treatment of IFALD, including a Phase 1 pharmacokinetic study and a Phase 3 placebo-controlled study. The retrospective, observational study was conducted in partnership with a large home health organization and examined data from 468 patients dependent on PN for six months or more. The primary endpoint of the study was to identify the proportion of patients dependent on PN with suspected liver disease defined as serum alkaline phosphatase (ALP) levels greater than 1.5 times the upper limit of normal (ULN). The study evaluated ALP levels from baseline up to 36 months to determine if there is a progressive component to cholestasis in IFALD and the degree to which medical management affected ALP levels. ALP is an established biomarker for cholestasis and a clinically meaningful indicator of IFALD severity and progression. Prolonged elevation of ALP is indicative of ongoing hepatocellular injury.


© S&P Capital IQ 2021
All news about PROTARA THERAPEUTICS, INC.
10/18PROTARA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Fina..
AQ
10/12PROTARA THERAPEUTICS : Thinking about buying stock in Protara Therapeutics, Standard Lithi..
PR
10/12Wall Street Set for Cautiously Higher Open, Earnings Season Eyed
MT
10/12PROTARA THERAPEUTICS : FDA Clears Protara's TARA-002 Trial in Non-Muscle Invasive Bladder ..
MT
10/12PROTARA THERAPEUTICS : FDA Clears IND Application for TARA-002 in Bladder Cancer
DJ
10/12PROTARA THERAPEUTICS : Announces FDA Clearance of Investigational New Drug Application for..
PU
10/12PROTARA THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statements ..
AQ
10/12PROTARA THERAPEUTICS : Announces FDA Clearance of Investigational New Drug Application for..
AQ
10/12Protara Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Applicat..
CI
09/17PROTARA THERAPEUTICS : to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTe..
AQ
More news
Analyst Recommendations on PROTARA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -55,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,68x
Yield 2021 -
Capitalization 80,3 M 80,3 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 27
Free-Float 81,1%
Chart PROTARA THERAPEUTICS, INC.
Duration : Period :
Protara Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTARA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 7,15 $
Average target price 40,00 $
Spread / Average Target 459%
EPS Revisions
Managers and Directors
Jesse Shefferman President, Chief Executive Officer & Director
Blaine T. Davis Chief Financial Officer & Secretary
Luke M. Beshar Chairman
Jacqueline Zummo Chief Scientific Operations Officer & Senior VP
Martín Sebastian Olivo Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTARA THERAPEUTICS, INC.-70.47%80
GILEAD SCIENCES, INC.14.76%83 830
BIONTECH SE230.50%65 071
WUXI APPTEC CO., LTD.25.14%64 894
REGENERON PHARMACEUTICALS16.48%58 504
VERTEX PHARMACEUTICALS-21.52%48 121